Alliance Health Networks forms healthcare advisory board
SALT LAKE CITY Alliance Health Networks, which is building a universe of social health networks focused on such specific health conditions as diabetes, has formed a healthcare advisory board. Among the founding members: pharmacy industry veteran Gordon Barker.
According to Alliance Health’s CEO, Stead Burwell, the advisory board is designed to provide Alliance Health executive management and its board of directors with industry insights, feedback and strategic counsel in support of its efforts to build online social health networks that bring together patients, caregivers and industry participants.
Alliance Health’s first social health network DiabeticConnect.com, has attracted the largest online population of people living with or treating diabetes, according to the company.
Barker has a nearly 40-year career in the pharmacy industry that includes 30 years with Thrifty PayLess Drug Stores, now Rite Aid. He started there as a pharmacist and eventually became president and CEO. He then served as CEO of Snyder Drug from 2005 through early 2009. In addition, Barker served as chairman of the board of the Juvenile Diabetes Research Found and currently serves on its board of chancellors.
Additional members of the advisory board include McKesson veteran, Richard Hawkins; and Robert Johnson, former chairman and CEO of PCS Health Systems, which is now part of CVS Caremark.
FDA approves Menveo
CAMBRIDGE, Mass. Novartis has received Food and Drug Administration approval for a vaccine for meningococcal disease, the Swiss drug maker’s vaccines division announced Monday.
The FDA approved Menveo (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197) to prevent meningococcal disease caused by Neisseria meningitidis bacteria.
The disease infects more than 500,000 people each year, killing as many as 1-in-7 who contract it; it is often fatal within 48 hours. About one-in-five who survive have serious side effects, including limb amputations, learning disabilities, seizures and paralysis.
“The FDA approval of Menveo is an important milestone for adolescent immunization in the United States,” Novartis vaccines division head Andrin Oswald said in a statement. “According to CDC estimates, approximately 16 million adolescents between the ages of 11 and 18 are at risk and remain unprotected against meningococcal disease.”
Watson CEO to serve as GPhA chairman
NAPLES, Fla. Watson Pharmaceuticals president and CEO Paul Bisaro will serve as the Generic Pharmaceutical Association’s chairman for 2010-2011, GPhA announced.
Bisaro has led Watson since 2007, after a stint as president and CEO of Barr Labs that began in 1999. He has served on GPhA’s board of directors since 2008, most recently as vice chairman.
“Paul will provide us with a steady hand as GPhA next navigates the often turbulent issues of health reform and the nation’s economic recovery,” GPhA president and CEO Kathleen Jaeger said. “GPhA looks forward to working with him, our board of directors and executive committee in what will be a challenging year.”
The organization also elected Mylan Pharmaceutical president Tony Mauro as vice chairman, New Chemic senior consultant Rosendo Ferran as secretary-treasurer. Nycomed U.S. CEO Paul McGarty, Teva North America president and CEO William Marth, Sandoz president and CEO Christine Mundkur and Zydus Pharmaceuticals president and CEO Joe Renner will serve as at-large members on the board’s executive committee.